Education
About Us
Working with TipRanks
Follow Us
Poseida Therapeutics, Inc. (PSTX)
NASDAQ:PSTX
RESEARCH TOOLSreports
Total Valuation
Poseida Therapeutics has a market cap or net worth of $925.92M. The enterprise value is $129.75M.
Market Cap$925.92M
Enterprise Value$129.75M
Share Statistics
Poseida Therapeutics has 97,465,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding97,465,000
Owned by Insiders0.43%
Owned by Institutions14.63%
Financial Efficiency
Poseida Therapeutics’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee―
Profits Per Employee―
Employee Count330
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of Poseida Therapeutics is ―. Poseida Therapeutics’s PEG ratio is ―.
PE Ratio―
PS Ratio6.14
PB Ratio―
Price to Fair Value―
Price to FCF―
Price to Operating Cash Flow―
PEG Ratio―
Income Statement
In the last 12 months, Poseida Therapeutics had revenue of ― and earned -123.43M in profits. Earnings per share was ―.
Revenue―
Gross Profit64.70M
Operating Income-129.50M
Pretax Income―
Net Income-123.43M
EBITDA-109.04M
Earnings Per Share (EPS)―
Cash Flow
In the last 12 months, operating cash flow was ― and capital expenditures ―, giving a free cash flow of ― billion.
Operating Cash Flow―
Free Cash Flow―
Free Cash Flow per Share―
Dividends & Yields
Poseida Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.52
52-Week Price Change235.69%
50-Day Moving Average6.80
200-Day Moving Average3.85
Relative Strength Index (RSI)75.33
Average Volume (3m)2.95M
Important Dates
Poseida Therapeutics upcoming earnings date is Mar 6, 2025, TBA Not Confirmed.
Last Earnings DateNov 7, 2024
Next Earnings DateMar 6, 2025
Ex-Dividend Date―
Financial Position
Poseida Therapeutics as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, Poseida Therapeutics has paid ― in taxes.
Income Tax―
Effective Tax Rate―
Enterprise Valuation
Poseida Therapeutics EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Poseida Therapeutics has ― in cash and marketable securities with 58.87M in debt, giving a net cash position of ― billion.
Cash & Marketable Securities―
Total Debt58.87M
Net Cash―
Net Cash Per Share―
Tangible Book Value Per Share―
Margins
Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin―
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for Poseida Therapeutics is $10.00, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$10.00
Price Target Upside5.26% Upside
Analyst ConsensusHold
Analyst Count3
Revenue Growth Forecast203.18%
EPS Growth Forecast57.79%